Ruben Rizzi, MD, is Vice-president of Global Regulatory Affairs at BioNTech. He joined the company in December 2019 and has worked on both immuno-oncology and infectious diseases developments. Since early 2020, he serves as global regulatory lead in the team in charge of the development, registration, and lifecycle of the COVID-19 mRNA vaccine co-developed with Pfizer (COMIRNATY). Before joining BioNTech, Ruben covered several areas of regulatory affairs, being responsible for oncology pipelines of small molecules and biologics, hospital anti-infectives, conjugated vaccines, liquid biopsy and IVD platforms, as well as contributing as regulatory and medical expert to pricing and market access initiatives and due diligence processes globally.